menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Celltrion Expands EU Biosimilar Portfolio With Two New Approvals

    BUSINESSWIRE

    Sandoz`s Biologic Enzeevu Receives Suppl Approval in US

    FDA

    EYLEA HD 8 mg Ph 3 Results for Macular Edema Retinal Vein

    GLOBENEWSWIRE

    EYLEA HD® 8 mg Shows Durable Vision Gains in Wet AMD 3-Year Data

    GLOBENEWSWIRE

    Lotus Pharma Partners for Eylea® Biosimilar FYB203 in APAC Region

    PHARMAWEB

    Teva To Commercialize Formycon’s Eylea Biosimilar In Europe, Israel

    GLOBENEWSWIRE

    Regeneron to expand high-dose Eylea`s label after Ph 3 win

    BIOSPACE

    EC grants approval to Sandoz’s biosimilar to treat retinal diseases

    FINANCIALXPRESS

    Sandoz Receives EC Approval for Afqlir® Biosimilar

    GLOBENEWSWIRE

    Eylea 8 mg Efficacy In Diabetic Macular Edema Confirmed At 3 Years

    INDPHARMAPOST

    EYLEA HD® Injection Shows Gains In Diabetic Macular Edema.

    GLOBENEWSWIRE

    Regeneron`s Biologic Eylea HD (Aflibercept) Receives Suppl Approval in US

    FDA

    Regeneron Pharma`s Biologic Eylea Receives Suppl Approval in US

    FDA

    Samsung Bioepis and Biogen Receive Positive CHMP

    GLOBENEWSWIRE

    EYLEA HD Data At EURETINA Shows Long-term Durability And Safety

    GLOBENEWSWIRE

    EMA Accepts Marketing Application For AVT06, Biosimilar To Eylea (Aflibercept)

    GLOBENEWSWIRE

    Alvotech Reports Record Revenues And Adjusted EBITDA For Q2 And H1 2024

    GLOBENEWSWIRE

    Sandoz Gets FDA Approval For Enzeevu, Boosting US Biosimilar Position

    GLOBENEWSWIRE

    European Commission Approves Roche`s Vabysmo For Retinal Vein Occlusion

    GLOBENEWSWIRE

    Altos Biologics Files for Approval of Aflibercept Biosimilar

    PR NEWSWIRE

    Formycon`s Biologic Ahzantive (aflibercept-mrbb) Receives Approval in US

    FDA

    Alvotech and STADA add to strategic alliance through denosumab partnership

    PRESS RELEASE

    4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 at Summit

    GLOBENEWSWIRE

    Enforcement Report - Week of June 5, 2024

    FDA

    Rezolute’s oral Eylea rival hits phase 2 goal, sending stock up

    FIERCE BIOTECH

    Biocon Gets US Approval For Biosimilar Aflibercept Yesafili

    PR NEWSWIRE

    Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

    INDINPHARMAPOST

    US FDA approves two biosimilars for blockbuster eye drug Eylea

    REUTERS

    Biocon Biologics’ Yesafili (aflibercept-jbvf) Receives Approval In U.S

    FDA

    Samsung Bioepis` Biologic Opuviz (aflibercept-yszy) Receives Approval in U.S.

    FDA

    Bayer de-emphasizes the impact of Roche`s Vabysmo on Eylea sales

    FIERCE PHARMA

    MS Pharma becomes Partner for the Commercialization of FYB203, Formycon

    PHARMIWEB

    Roche’s soaring Vabysmo sales challenge Regeneron’s Eylea

    FIERCE PHARMA

    Dupixent COPD delay possible, Eylea down 2%, Regeneron says

    FIERCE PHARMA

    EYLEA® HD Data in Retinal Diseases at ARVO 2024

    GLOBENEWSWIRE

    US FDA warns of harmful reactions to fake Botox injections

    REUTERS

    US accuses Regeneron of fraudulent price reporting for eye drug

    REUTERS

    Bayer Pharmaceuticals advances next generation of blockbuster medicines

    PRESS RELEASE

    Aflibercept 8 mg clinical study data now published in The Lancet

    PRESS RELEASE

    EYLEA Injection 8 mg Pivotal Data in wAMD and DME Published in The Lancet

    GLOBENEWSWIRE

    Regeneron touts `favorable` physician reports on Eylea HD

    FIERCE PHARMA

    New Eylea™ 8 mg approved in Japan

    PRESS RELEASE

    New Eylea™ 8 mg approved in EU

    PRESS RELEASE

    Alvotech Study Results Demonstrate Therapeutic Equivalence between AVT06

    GLOBENEWSWIRE

    Regeneron Gains After Eye-Drug Patent Victory Over Viatris

    BLOOMBERG

    Regeneron`s Biologic Eylea (aflibercept) Receives Approval in the U.S.

    FDA

    Sanofi`s Biologic Zaltrap (ziv-aflibercept) Receives Approval in the U.S.

    FDA

    Biocon Biologics receives MHRA Approval for Biosimilar Aflibercept ‘Yesafili’

    INDIAN PHARMA POST

    Bayer’s aflibercept 8 mg recommended for approval in EU

    PRESS RELEASE

    With high-dose Eylea launch, Regeneron eyes battle with Roche

    FIERCE PHARMA

    EYLEA Injection 8 mg Data Presentations at AAO Reinforce Efficacy

    GLOBENEWSWIRE

    EYLEA Injection 8 mg Results from Pivotal PULSAR Trial Presented

    GLOBENEWSWIRE

    Bayer presents new 60- and 96-week data on aflibercept 8 mg for patients with neovascular (wet) age-related macular degeneration and diabetic macular edema

    PRESS RELEASE

    After wet AMD trial, Unity gathers around diabetic macular edema

    FIERCE BIOTECH

    Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data

    GLOBENEWSWIRE

    Regeneron`s Biologic Eylea (Aflibercept) Receives Approval in the U.S.

    FDA

    Novartis` Eylea biosimilar adds to pressure on Regeneron`s star

    FIERCE PHARMA

    Aflibercept 8 mg first to achieve sustained vision gains with more than 70% of patients extended to intervals between 16 and 24 weeks in wet age-related macular degeneration at two years

    PRESS RELEASE

    Regeneron expects FDA decision on higher-dose Eylea this year

    REUTERS

    Aflibercept 8 Mg Two-Year Results From Pivotal Photon Trial Presented At Asrs

    PRESS RELEASE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.